2007乳腺癌nccn临床实践指南(中国版).pdf

Copyright © National Comprehensive Cancer Network 2007. All rights reserved. “NCCN”, the NCCN logo, and “National Comprehensive Cancer Network” are registered trademarks of the National Comprehensive Cancer Network. The Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Breast Cancer Guideline 2007 is the Chinese adapted version of NCCN Clinical Practice Guidelines in Oncology-Breast Cancer Guideline, V.2.2007 as permitted and endorsed by NCCN. It is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field.The original guideline and Chinese edition are both available at: http://www.nccn.org. To view the most recent and complete version of the guideline, go online to www.nccn.org. These Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN.These Guidelines are a work in progress that will be refined as often as new significant data becomes available. The NCCN Guidelines are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN guideline is expected to use independent medical judgment in the context of individual clinical circumstance to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.This publication should not be used for commercial purpose. It is provided for free to Chinese medical professions with the support of the unrestrictive educational grant of Bristol-Myers Squibb Co. Ltd. which exerts no influence to the formation of The Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Breast Cancer Guideline 2007.NCCN ®肿瘤学临床实践指南(中国版) 2007年 第一版© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. The Chinese edition 2007 is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field. Translated and adapted with permission and endorsement from the National Comprehensive Cancer Network. To view the most recent and complete version of this or any other guideline, visit www.nccn.org.乳 腺 癌-2-*Robert W. Carlson, MD/Chair † Stanford Hospital and Clinics*Benjamin O. Anderson, MD ¶ Fred Hutchinson Cancer Research Center/Seattle Cancer Care AllianceHarold J. Burstein, MD, PhD † Dana-Farber/Partners CancerCareW. Bradford Carter, MD ¶ H. Lee Moffitt Cancer Center 353:1659-72.BINV-H 6-4NCCN ®浸 润 性 乳 腺 癌© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. The Chinese edition 2007 is the collaborative outcome of the National Comprehensive Cancer Network and Chinese key opinion leaders of the field. Translated and adapted with permission and endorsement from the National Comprehensive Cancer Network. To view the most recent and complete version of this or any other guideline, visit www.nccn.org.肿瘤学临床实践指南(中国版) 2007年 第一版-35-AC→T+曲妥珠单抗[12]???? 60 mg/m2 IV d1 ???? 600 mg/m2 IV d1 21??1?????4??? ?? ??? 175 mg/m2 IV 3?? d1 21??1?????4??? ? ??? 80 mg/m2 IV 1?? ??1???12? ? ????? 4 mg/kg IV????? ????????? ?? ????? 2 mg/kg IV???1??? 1?????????6 mg/kg IV? ?3?1???????????? ????1? ????3???6???9?????? ???多西他赛+曲妥珠单抗→FEC [13] ???? 100 mg/m2 IV 1?? d1 21??1?????3??? ? ????? 4 mg/kg IV????? ?????????? ?? ????? 2 mg/kg IV???1?? ?9?? ?? 5-FU 600 mg/m2 IV d l ???? 60 mg/m2 IV d1 ???? 600 mg/m2 IV d1 21??1?????3??? ??????FEC???????12?? ?36????????THC（多西他赛/卡铂/曲妥珠单抗）[14] ???? 75 mg/m2 IV d1 ?? ?? AUC=6 IV d1 21??1?????6??? ? ????? 4 mg/kg IV??1? ?? ????? 2 mg/kg IV??17? ?? ?????6 mg/kg IV??3?1?? ?1? ????3???6???9?????? ???化疗序贯曲妥珠单抗[15] ??????????????? 4??? ?? ???????8 mg/kg IV ?? ?????6 mg/kg IV??21?1?? ?1? ????3???6???9?????? ???AC→多西他赛+曲妥珠单抗[14] ???? 60 mg/m2 IV d1 ???? 600 mg/m2 IV d1 21??1?????4??? ?? ???? 100 mg/m2 21??1?????4??? ? ????? 4 mg/kg IV???? ?? ????? 2 mg/kg IV???1?? ?11? ?? ?????6 mg/kg IV??21?1?? ?1? ????3???6???9?????? ???T+曲妥珠单抗→FEC+曲妥珠单抗[16]?????4 mg/kg IV????? ??????? ?? ????? 2 mg/kg IV???1?? ?23? ? ??? 225 mg/m2 IV 24?? 21??1?????4??? ?? 5-FU 500 mg/m2 IV d l?4 ???? 75 mg/m2 IV d1 ???? 500 mg/m2 IV d1 21??1?????4???● ●●●●●●●●● ● ●●●●●●●●●● ●●●●●●●●● ● ●含曲妥珠单抗的辅助及新辅助化疗代表方案** 抗癌药物的选择、剂量和应用以及相关毒性的处理很复杂。

由于意料之中的毒性反应、个体差异、既往治疗和合并症的存在，有必要改变用药剂量和方案以及启用支持治疗最佳地给予抗癌药物 治疗需要一支在应用抗癌药和处理相关毒性方面具有丰富经验的医疗团队BINV-H 6-5辅助化疗方案新辅助化疗方案NCCN ®© National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and thi。